MCT1-dependent energetic failure and neuroinflammation underlie optic nerve degeneration in Wolfram syndrome mice
Greta Rossi, Gabriele OrdazzoiD, Niccolò N VanniiD, Valerio CastoldiiD, Angelo IannielliiD, Dario Di SilvestreiD, Edoardo Niccolò BelliniiD, Letizia BernardoiD, Serena Gea GiannelliiD, Mirko LuoniiD, Sharon MuggeoiD, Letizia LeocaniiD, Pierluigi MauriiD, Vania BroccoliiD
Abstract
Wolfram syndrome 1 (WS1) is a rare genetic disorder caused by mutations in the WFS1 gene leading to a wide spectrum of clinical dysfunctions, among which blindness, diabetes and neurological deficits are the most prominent. WFS1 encodes for the endoplasmic reticulum (ER) resident transmembrane protein Wolframin with multiple functions in ER processes. However, the WFS1-dependent etiopathology in retinal cells is unknown. Herein, we showed that Wfs1 mutant mice developed early retinal electrophysiological impairments followed by marked visual loss. Interestingly, axons and myelin disruption in the optic nerve preceded the degeneration of the retinal ganglion cell bodies in the retina. Transcriptomics at pre-degenerative stage revealed the STAT3-dependent activation of proinflammatory glial markers with reduction of the homeostatic and pro-survival factors Glutamine synthetase and BDNF. Furthermore, label-free comparative proteomics identified a significant reduction of the monocarboxylate transport isoform 1 (MCT1) and its partner Basigin that are highly enriched on retinal astrocytes and myelin-forming oligodendrocytes in optic nerve together with Wolframin. Loss of MCT1 caused a failure in lactate transfer from glial to neuronal cell bodies and axons leading to a chronic hypometabolic state. Thus, this bioenergetic impairment is occurring concurrently both in the axonal regions and cell bodies of the retinal ganglion cells, selectively endangering their survival while impacting less on other retinal cells. This metabolic dysfunction occurs months before the frank RGC degeneration suggesting an extended time window for intervening with new therapeutic strategies focused on boosting retinal and optic nerve bioenergetics in WS1.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 20
- FWCI
- 1.78
- Field percentile
- top 15%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- WFS1E864K in humans and mice causes Wolfram-like syndrome optic atrophy via early axonal mitochondrial dysfunction
Hernán H. Diéguez, Kevin Dubois, … Élodie M. Richard·bioRxiv·Oct 13, 2025
- Synaptic Alterations Are Preceding the Axonal Loss in Optic Atrophy of Wolfram Syndrome Mouse Model
Venu Gurram, William An, … Fumihiko Urano·Frontiers in NeurosciencePeer-reviewed·May 22, 2026
- A deep phenotyping study in mouse and iPSC models to understand the role of oligodendroglia in optic neuropathy in Wolfram syndrome
K. Ahuja, Marjan Vandenabeele, … Lies De Groef·Acta Neuropathologica CommunicationsPeer-reviewed·Aug 28, 2024
- The Wolfram-like variant WFS1E864K destabilizes MAM and compromises autophagy and mitophagy in human and mice.
Simone Patergnani, Méghane S. Bataillard, … Élodie M. Richard·bioRxiv·Nov 16, 2023
- Anti-inflammatory effects of WFS1 in pancreatic beta-cells
Shuntaro Morikawa, Lindsey Blacher, … Fumihiko Urano·bioRxiv·Feb 9, 2022
- Genotype and Clinical Characteristics of Patients with Wolfram Syndrome and WFS1-related Disorders
Evan M. Lee, Megha Verma, … Fumihiko Urano·Frontiers in GeneticsPeer-reviewed·Jun 21, 2023